Feb 23, 2018 The unmatched clarity of image with the most powerful camera on the market. Easy to use, intuitive use and one-touch buttons to activate features. Light, portable, customizable. This is the perfect electronic video magnifier for anyone with low vision and age related macular degeneration. Age-Related Macular Degeneration. Age-related macular degeneration (AMD) is the leading cause of vision loss among people age 50 and older, and it is most likely to occur in people over the age of 60. With AMD, the macula is damaged over time. The macula is a small point near the center of the retina that is responsible for creating sharp.
PARIS--(BUSINESS WIRE)--Regulatory News:
Feb 01, 2014 The number of people with age-related macular degeneration (y ij) can be specified as binomially distributed: y ij ∼ Binomial(n ij,p ij), where n ij is the total number of participants and p ij is the prevalence of age-related macular degeneration in i th the study of the j th category of the varying covariate (eg, each study might consist of.
Age Related Macular Degeneration. DIY Project at Home. This website may has many information about Dry Macular Degeneration. If you are looking for Dry Macular Degeneration you've come to the correct place. We have 19 pictures about Dry Macular Degeneration including photos, wallpapers, images, pictures, and more.
Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces successful activations of PRIMA, its new generation miniature wireless photovoltaic sub-retinal implant, in the first 3 patients with severe vision loss from atrophic dry Age-related Macular Degeneration (AMD), out of the 5 planned in the French feasibility study started in December 2017.
The initial observations are encouraging only few weeks following the first implantations:
In all 3 patients, the miniature wireless chips were successfully implanted under the atrophic macula via a minimal invasive surgical procedure, and the chip placement is stable throughout the postoperative follow-up period,
All 3 patients perceive light patterns, within the expected ranges of light intensity, in the area where no light perception remained previously due to loss of light-sensitive cells. Resolution of the perceived signal matches the expectations.
As planned by the clinical protocol, patients are undergoing training and readaptation.
Khalid Ishaque, Chief Executive Officer of Pixium Vision, stated: “Following activation of the implants in the first 3 patients, the initial observations are exciting for the Company. They confirm PRIMA’s ability to restore light perception from the retinal atrophic zone of these dry-AMD patients, where no visual sensitivity remained prior to the treatment. This is in line with the expectations based on preclinical experiments. The feasibility studies will advance with 2 more patients to be recruited in Paris, and additional 5 patients in the US feasibility trial which is to begin shortly. We are confident that PRIMA is a feasible therapeutic option to restore some useful vision in patients blinded by retinal degeneration.”
The French feasibility study1 with PRIMA is a 36-month, 5-patient clinical study, designed to evaluate the safety and function of the wireless sub-retinal PRIMA chip in eliciting visual light perception, with an interim 6-month analysis enabling to prepare and start also for the pivotal clinical study in EU.
ABOUT PRIMA
PRIMA is a new generation miniaturized and totally wireless sub-retinal implant. The PRIMA implant is a micro photovoltaic chip of 2x2 millimeters and 30 microns thick, equipped with 378 electrodes. Implanted under the retina via a less invasive surgical procedure, it acts like a tiny solar panel that is powered by pulsed near infrared light through a miniaturized projector integrated in a pair of augmented reality-like glasses, along with a mini-camera, worn by the implanted subject. PRIMA is designed to compensate for severe vision loss from retinal dystrophies, initially atrophic dry Age-related Macular Degeneration (dry AMD), a significant unmet medical need with currently no curative therapeutic solution, and at later stage also Retinitis Pigmentosa (RP).
ABOUT AGE-RELATED MACULAR DEGENERATION (AMD)
Age-related macular degeneration2 is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe, impacting an estimated 12 to 15 million people worldwide which is continuously growing due to ageing population. There are two forms of AMD, the wet form, representing ~20% of AMD, where treatment like anti-VEGF injections is available slow down the disease progression, and the dry form, representing ~80% of AMD, where there is currently no curative treatment available. More than 4 million patients are afflicted with advanced dry AMD In Europe and the United States. Patients suffering from this retinal disorder start by losing their central vision (responsible for visual precision and details, for example, required for reading and face recognition) and progressively become blind.
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study1 in Human with PRIMA, its new generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Stanford University in California, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” par Bpifrance.
For more information, please visit: www.pixium-vision.com; And follow us on: Twitter: @PixiumVision; facebook: www.facebook.com/pixiumvision LinkedIn: www.linkedin.com/company/pixium-vision
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext CAC All Shares index
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements. Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 'Risk Factors' of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com). IRIS® is a trademark of Pixium-Vision SA
1 Feasibility Study of Compensation for Blindness with the PRIMA System in Patients with Dry Age Related Macular Degeneration (PRIMA FS) https://www.clinicaltrials.gov/ct2/show/NCT03333954 2http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30393-5/fulltext
https://www.nih.gov/coronavirus.
As of October 1, 2020, the National Library of Medicine (NLM) will no longer offer Genetics Home Reference as a stand-alone website. Instead, much of the content from Genetics Home Reference has been transferred to MedlinePlus, the NLM’s flagship website for health information for patients, families, and the general public.
Please visit MedlinePlus Genetics (https://medlineplus.gov/genetics) to access genetics information and learn more about this change.
Skip to main content
Home
Health Conditions
Age-related macular degeneration Printable PDFOpen AllClose AllEnable Javascript to view the expand/collapse boxes.
Description
Age-related macular degeneration is an eye disease that is a leading cause of vision loss in older people in developed countries. Genetec video player for mac os. Subtle abnormalities indicating changes in vision may occur in a person's forties or fifties. Distorted vision and vision loss usually become noticeable in a person's sixties or seventies and tend to worsen over time.
Age-related macular degeneration
Credit: National Eye Institute/National Institutes of Health
Use of illustrations and other content
' href='/art/large/age-related-macular-degeneration.png' target='_blank'>mainly affects central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The vision loss in this condition results from a gradual deterioration of light-sensing cells in the tissue at the back of the eye that detects light and color (
Credit: Alila Medical Media/Shutterstock.com
Use of illustrations and other content
' href='/art/large/structure-of-the-retina.jpeg' target='_blank'>the retina). Specifically, age-related macular degeneration affects a
Credit: National Eye Institute/National Institutes of Health
Use of illustrations and other content
' target='_blank' href='/art/large/retina-age-related-macular-degeneration.png'>small area near the center of the retina, called the
Credit: National Eye Institute/National Institutes of Health
Use of illustrations and other content
' href='/art/large/normal-eye-anatomy-2.png' target='_blank'>macula, which is responsible for central vision. Side (peripheral) vision and night vision are generally not affected, but slow adjustment of vision to darkness (dark adaptation) and reduced dim light (scotopic) vision often occur in the early stages of the disease.
Researchers have described two major types of age-related macular degeneration, known as the dry form and the wet form. The dry form is much more common, accounting for 85 to 90 percent of all cases of age-related macular degeneration. It is characterized by a buildup of yellowish deposits called drusen beneath the retina and vision loss that worsens slowly over time. The most advanced stage of dry age-related macular degeneration is known as geographic atrophy, in which areas of the macula waste away (atrophy), resulting in severe vision loss. Dry age-related macular degeneration typically affects vision in both eyes, although vision loss often occurs in one eye before the other.
In 10 to 15 percent of affected individuals, the dry form progresses to the wet form of age-related macular degeneration. The wet form is characterized by the growth of abnormal, fragile blood vessels underneath the macula. These vessels leak blood and fluid, which damages the macula and makes central vision appear blurry and distorted. The wet form of age-related macular degeneration is associated with severe vision loss that can worsen rapidly.
Credit: Alila Medical Media/Shutterstock.com
Use of illustrations and other content
' target='_blank'>
Credit: Alila Medical Media/Shutterstock.com
Use of illustrations and other content
' target='_blank'> Enlarge
Frequency
It is estimated that 8 percent of people around the world have signs of age-related macular degeneration. The condition currently affects about 11 million Americans and 170 million people worldwide, and the prevalence is expected to increase over the coming decades as the proportion of older people in the population increases.
For reasons that are unclear, age-related macular degeneration affects individuals of European descent more frequently than African Americans in the United States.
Related Information
What information about a genetic condition can statistics provide?
Why are some genetic conditions more common in particular ethnic groups?
Causes
Age-related macular degeneration results from a combination of genetic and environmental factors. Many of these factors have been identified, but some remain unknown.
Researchers have considered changes in many genes as possible risk factors for age-related macular degeneration. The best-studied of these genes are involved in a part of the body's immune response known as the complement system. This system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. Genetic changes in and around several complement system genes, including the CFH gene, contribute to a person's risk of developing age-related macular degeneration. It is unclear how these genetic changes are related to the retinal damage and vision loss characteristic of this condition.
Changes on the long (q) arm of chromosome 10 in a region known as 10q26 are also associated with an increased risk of age-related macular degeneration. The 10q26 region contains two genes of interest, ARMS2 and HTRA1. Changes in both genes have been studied as possible risk factors for the disease. However, because the two genes are so close together, it is difficult to tell which gene is associated with age-related macular degeneration risk, or whether increased risk results from variations in both genes.
Other genes that are associated with age-related macular degeneration include genes involved in transporting and processing high-density lipoproteins (HDL, also known as 'good' cholesterol) and genes that have been associated with other forms of macular disease.
Researchers have also examined nongenetic factors that contribute to the risk of age-related macular degeneration. Age appears to be the most important risk factor; the chance of developing the condition increases significantly as a person gets older. Smoking is another established risk factor for age-related macular degeneration. Other factors that may increase the risk of this condition include high blood pressure; heart disease; a diet that is high in fat, high in easily digested foods (high glycemic index), or low in certain nutrients (such as antioxidants and zinc); obesity; and exposure to ultraviolet (UV) rays from sunlight. However, it is unclear how these factors influence the risk of developing age-related macular degeneration.
Learn more about the genes associated with age-related macular degeneration
ABCA4
APOE
ARMS2
ASPM
BEST1
C2
C3
C9
CETP
CFB
CFH
CFHR1
CFHR2
CFHR3
CFHR4
CFHR5
CFI
COL8A1
COL10A1
CST3
CX3CR1
ELOVL4
ERCC6
F13B
FBLN5
FILIP1L
FRK
HMCN1
HTRA1
LIPC
MAP2
TIMP3
TNFRSF10A
VEGFA
Related Information
What is a gene?
What is a gene mutation and how do mutations occur?
How can gene mutations affect health and development?
More about Mutations and Health
Inheritance Pattern
Age-related macular degeneration usually does not have a clear-cut pattern of inheritance, although the condition appears to run in families in some cases. An estimated 15 to 20 percent of people with age-related macular degeneration have at least one
An individual shares half his/her genes with each parent and each offspring. An individual shares an on average half his/her genes with each sibling
Credit: GeneReviews, University of Washington, Seattle
Use of illustrations and other content
' target='_blank' href='/art/large/first-degree-relative.jpeg'>first-degree relative (such as a sibling or parent) with the condition.
Related Information
What does it mean if a disorder seems to run in my family?
What are the different ways in which a genetic condition can be inherited?
Prevent Blindness: Age-Related Macular Degeneration (AMD) Test - Amsler Grid
Related Information
How we cover diagnosis and management of health conditions
How are genetic conditions diagnosed?
How are genetic conditions treated or managed?
How can I find a genetics professional in my area?
Other Names for This Condition
age-related maculopathy
AMD
ARMD
macular degeneration, age-related
Related Information
How are genetic conditions and genes named?
Additional Information & Resources
Health Information from MedlinePlus (3 links)
Encyclopedia: Macular Degeneration (Image)
Encyclopedia: Macular Degeneration - Age-Related
Health Topic: Macular Degeneration
Genetic and Rare Diseases Information Center (1 link)
Macular degeneration
Additional NIH Resources (1 link)
National Eye Institute
Educational Resources (7 links)
American Academy of Ophthalmology
Centers for Disease Control and Prevention
JAMA Patient Page
MalaCards: macular degeneration, age-related, 1
Merck Manual Consumer Version
Orphanet: Age-related macular degeneration
U.S. Department of Transportation: Driving When You Have Macular Degeneration
Patient Support and Advocacy Resources (6 links)
American Macular Degeneration Foundation
BrightFocus Foundation
Foundation Fighting Blindness
MD Support
Prevent Blindness: The AMD Learning Center
Retina International
Scientific Articles on PubMed (1 link)
PubMed
Catalog of Genes and Diseases from OMIM (15 links)
MACULAR DEGENERATION, AGE-RELATED, 1
MACULAR DEGENERATION, AGE-RELATED, 2
MACULAR DEGENERATION, AGE-RELATED, 4
MACULAR DEGENERATION, AGE-RELATED, 5
MACULAR DEGENERATION, AGE-RELATED, 6
MACULAR DEGENERATION, AGE-RELATED, 7
MACULAR DEGENERATION, AGE-RELATED, 8
MACULAR DEGENERATION, AGE-RELATED, 9
MACULAR DEGENERATION, AGE-RELATED, 10
MACULAR DEGENERATION, AGE-RELATED, 11
MACULAR DEGENERATION, AGE-RELATED, 12
MACULAR DEGENERATION, AGE-RELATED, 13
MACULAR DEGENERATION, AGE-RELATED, 14
MACULAR DEGENERATION, AGE-RELATED, 15
NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION
Medical Genetics Database from MedGen (1 link)
Age-related macular degeneration
Projector For Macular Degeneration Icd 10
Sources for This Page
Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, Tosakulwong N, Pericak-Vance MA, Campochiaro PA, Klein ML, Tan PL, Conley YP, Kanda A, Kopplin L, Li Y, Augustaitis KJ, Karoukis AJ, Scott WK, Agarwal A, Kovach JL, Schwartz SG, Postel EA, Brooks M, Baratz KH, Brown WL; Complications of Age-Related Macular Degeneration Prevention Trial Research Group, Brucker AJ, Orlin A, Brown G, Ho A, Regillo C, Donoso L, Tian L, Kaderli B, Hadley D, Hagstrom SA, Peachey NS, Klein R, Klein BE, Gotoh N, Yamashiro K, Ferris Iii F, Fagerness JA, Reynolds R, Farrer LA, Kim IK, Miller JW, Cortón M, Carracedo A, Sanchez-Salorio M, Pugh EW, Doheny KF, Brion M, Deangelis MM, Weeks DE, Zack DJ, Chew EY, Heckenlively JR, Yoshimura N, Iyengar SK, Francis PJ, Katsanis N, Seddon JM, Haines JL, Gorin MB, Abecasis GR, Swaroop A. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7401-6. doi: 10.1073/pnas.0912702107. Epub 2010 Apr 12.
Citation on PubMed or Free article on PubMed Central
Citation on PubMed or Free article on PubMed Central
Curcio CA, Owsley C, Jackson GR. Spare the rods, save the cones in aging and age-related maculopathy. Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2015-8. Review.
Citation on PubMed
Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP Jr, Buitendijk GH, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan CC, Cheng CY, Chew EY, Chin KA, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G, Ioannidis JP, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, N Keilhauer C, Khan JC, Kim IK, Kiyohara Y, Klein BE, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ, Meitinger T, Mitchell P, Mohand-Saïd S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJ, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel JA, Schaumberg DA, Scholl HP, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L, Vingerling JR, Vithana EN, Webster AR, Wichmann HE, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird PN, Gorin MB, Wang JJ, Klaver CC, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates JR, Swaroop A, Weber BH, Kubo M, Deangelis MM, Léveillard T, Thorsteinsdottir U, Haines JL, Farrer LA, Heid IM, Abecasis GR; AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013 Apr;45(4):433-9, 439e1-2. doi: 10.1038/ng.2578. Epub 2013 Mar 3.
Citation on PubMed or Free article on PubMed Central
Hampton T. Genetic research provides insights into age-related macular degeneration. JAMA. 2010 Oct 13;304(14):1541-3. doi: 10.1001/jama.2010.1411.
Citation on PubMed
Jackson GR, Scott IU, Kim IK, Quillen DA, Iannaccone A, Edwards JG. Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014 Mar 10;55(3):1427-31. doi: 10.1167/iovs.13-13745.
Citation on PubMed or Free article on PubMed Central
Neale BM, Fagerness J, Reynolds R, Sobrin L, Parker M, Raychaudhuri S, Tan PL, Oh EC, Merriam JE, Souied E, Bernstein PS, Li B, Frederick JM, Zhang K, Brantley MA Jr, Lee AY, Zack DJ, Campochiaro B, Campochiaro P, Ripke S, Smith RT, Barile GR, Katsanis N, Allikmets R, Daly MJ, Seddon JM. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7395-400. doi: 10.1073/pnas.0912019107. Epub 2010 Apr 12.
Citation on PubMed or Free article on PubMed Central
Owsley C, McGwin G Jr, Clark ME, Jackson GR, Callahan MA, Kline LB, Witherspoon CD, Curcio CA. Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration. Ophthalmology. 2016 Feb;123(2):344-51. doi: 10.1016/j.ophtha.2015.09.041. Epub 2015 Oct 30.
Citation on PubMed or Free article on PubMed Central
Citation on PubMed or Free article on PubMed Central
Seddon JM, Silver RE, Kwong M, Rosner B. Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2192-202. doi: 10.1167/iovs.14-15841.
Citation on PubMed or Free article on PubMed Central
Swaroop A, Chew EY, Rickman CB, Abecasis GR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10:19-43. doi: 10.1146/annurev.genom.9.081307.164350. Review.
Citation on PubMed or Free article on PubMed Central
Thakkinstian A, McEvoy M, Chakravarthy U, Chakrabarti S, McKay GJ, Ryu E, Silvestri G, Kaur I, Francis P, Iwata T, Akahori M, Arning A, Edwards AO, Seddon JM, Attia J. The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2012 Sep 1;176(5):361-72. doi: 10.1093/aje/kws031. Epub 2012 Aug 5. Review.
Citation on PubMed
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. Review.
Citation on PubMed
den Hollander AI, de Jong EK. Highly penetrant alleles in age-related macular degeneration. Cold Spring Harb Perspect Med. 2014 Nov 6;5(3):a017202. doi: 10.1101/cshperspect.a017202. Review.
GeneEd resources available on Genetics Home Reference
Genetics Home Reference results available from MedlinePlus Connect
Treatment For Macular Degeneration
You Might Also Like
What is direct-to-consumer genetic testing?
What are genome editing and CRISPR-Cas9?
What is precision medicine?
What is newborn screening?
Reviewed: May 2020Published:
Projector For Macular Degeneration
August 17, 2020
Projector For Macular Degeneration Symptoms
The resources on this site should not be used as a substitute for professional medical care or advice. Users with questions about a personal health condition should consult with a qualified healthcare professional.